Zhanna Kobalava
15 Papers
Zhanna Kobalava is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
7.7K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
1.1K
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker,Jean G. MacFadyen,Brendan M. Everett,Peter Libby,Tom Thuren,Robert J. Glynn,John J.P. Kastelein,Wolfgang Koenig,Jacques Genest,Alberto J. Lorenzatti,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Les Forgosh,Barry Harris,Monica Ligueros +55 more
TL;DR: The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment, and suggest that lower is better for inflammation reduction with canakinUMab.
753
Cardiac device-related infective endocarditis need for lead extraction whatever the device according to the ESC EORP EURO-ENDO registry
Erwan Donal,Christophe Tribouilloy,Anita Sadeghpour,Cécile Laroche,Ana Clara Tude Rodrigues,Maria do Carmo Pereira Nunes,Duk-Hyun Kang,Zhanna Kobalava,Michele De Bonis,Rafal Dworakowski,Branislava Ivanovic,Maria Holicka,Takeshi Kitai,Inês Cruz,Olivier Huttin,Paolo Colonna,Patrizio Lancellotti,Gilbert Habib +17 more
TL;DR: In this paper , the authors report the management and prognosis of Cardiac Device-related Infective Endocarditis (CDRIE) in real life and the rate of device extraction in clinical practice and the management of patients with patients with left heart infective endocarditis and an apparently non-infected CD (LHIE+) are not well described.
11
Hiv-related atherosclerosis: state-of-the-art-review.
Ashot Avagimyan,Nana Pogosova,Lev V Kakturskiy,Mohammad Sheibani,O. I. Urazova,G.A. Navasardyan,Federica Fogacci,Mattia Galli,Luciano Agati,Zhanna Kobalava,Davood Shafie,Mario Marzilli,L. E. Gogiashvili,Nizal Sarrafzadegan +13 more
TL;DR: In this article , the authors evaluated the pathological aspects of HIV-induced atherosclerosis and found that people living with HIV are more prone to the age-related diseases, especially atheros sclerosis.
6